{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:10:44Z","timestamp":1774699844701,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jaut.2024.103299","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T12:20:01Z","timestamp":1722601201000},"page":"103299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Earlier vs. later time period of COVID-19 infection and emergent autoimmune signs, symptoms, and serologies"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1701-6258","authenticated-orcid":false,"given":"Emily G.","family":"Oakes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eilish","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine A.","family":"Buhler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongshu","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misti","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryne","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ifeoluwakiisi","family":"Adejoorin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong","family":"Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Ellrodt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siobhan M.","family":"Case","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel H.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Helena","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta Vezza","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak A.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May Y.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen H.","family":"Costenbader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2024.103299_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101783","article-title":"Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study","volume":"56","author":"Chang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jaut.2024.103299_bib2","article-title":"Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study","author":"Tesch","year":"2023","journal-title":"Clin. Rheumatol."},{"issue":"10","key":"10.1016\/j.jaut.2024.103299_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36120","article-title":"Autoimmune and autoinflammatory connective tissue disorders following COVID-19","volume":"6","author":"Lim","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jaut.2024.103299_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102154","article-title":"Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study","volume":"63","author":"Peng","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.jaut.2024.103299_bib5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12916-023-03049-5","article-title":"Incidence of immune-mediated inflammatory diseases following COVID-19: a matched cohort study in UK primary care","volume":"21","author":"Syed","year":"2023","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.jaut.2024.103299_bib6","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1038\/s41467-021-25509-3","article-title":"New-onset IgG autoantibodies in hospitalized patients with COVID-19","volume":"12","author":"Chang","year":"2021","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.jaut.2024.103299_bib7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/cts.12805","article-title":"Clinical and autoimmune characteristics of severe and critical cases of COVID-19","volume":"13","author":"Zhou","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.jaut.2024.103299_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102557","article-title":"The correlation between SARS-CoV-2 infection and rheumatic disease","volume":"19","author":"Gao","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.jaut.2024.103299_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003022","article-title":"Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group","volume":"9","author":"Ursini","year":"2023","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.jaut.2024.103299_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102883","article-title":"Rheumatological complications of Covid 19","volume":"20","author":"Zacharias","year":"2021","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"10.1016\/j.jaut.2024.103299_bib11","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s10067-021-05691-x","article-title":"COVID-19 and the clinical course of rheumatic manifestations","volume":"40","author":"Ahmed","year":"2021","journal-title":"Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.jaut.2024.103299_bib12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2020.12603","article-title":"Persistent symptoms in patients after acute COVID-19","volume":"324","author":"Carf\u00ec","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jaut.2024.103299_bib13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0140-6736(20)32656-8","article-title":"6-month consequences of COVID-19 in patients discharged from hospital: a cohort study","volume":"397","author":"Huang","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2024.103299_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.151544","article-title":"Duration of post-COVID-19 symptoms are associated with sustained SARS-CoV-2 specific immune responses","author":"Files","year":"2021","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.jaut.2024.103299_bib15","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/infdis\/jiab490","article-title":"Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection","volume":"224","author":"Peluso","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.jaut.2024.103299_bib16","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00134-021-06408-z","article-title":"COVID-19-associated autoimmunity as a feature of acute respiratory failure","volume":"47","author":"Trahtemberg","year":"2021","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.jaut.2024.103299_bib17","article-title":"Epstein-barr virus and systemic autoimmune diseases","volume":"11","author":"Houen","year":"2020","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.jaut.2024.103299_bib18","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41590-020-00814-z","article-title":"Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19","volume":"21","author":"Woodruff","year":"2020","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.jaut.2024.103299_bib19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/20009666.2021.1978154","article-title":"Mortality due to COVID-19 infection: a comparison of first and second waves","volume":"11","author":"Oladunjoye","year":"2021","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"10.1016\/j.jaut.2024.103299_bib20","unstructured":"CDC SARS-CoV-2 Variant Classifications and Definitions. Center for Disease Control and Prevention. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/variants\/variant-classifications.html#anchor_1679059484954."},{"key":"10.1016\/j.jaut.2024.103299_bib21","unstructured":"CoVariants.org. https:\/\/covariants.org\/."},{"issue":"15","key":"10.1016\/j.jaut.2024.103299_bib22","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.jaut.2024.103299_bib23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1473-3099(22)00154-2","article-title":"Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study","volume":"22","author":"Bager","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"22","key":"10.1016\/j.jaut.2024.103299_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214146","article-title":"Cytokine profiling in different SARS-CoV-2 genetic variants","volume":"23","author":"Korobova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.jaut.2024.103299_bib25","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s40121-022-00698-6","article-title":"Excess of post-acute sequelae of COVID-19 after the first wave of the pandemic","volume":"11","author":"Scherlinger","year":"2022","journal-title":"Infect. Dis. Ther."},{"issue":"16","key":"10.1016\/j.jaut.2024.103299_bib26","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jaut.2024.103299_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/ar4342","article-title":"Anti-citrullinated peptide autoantibodies, human leukocyte antigen shared epitope and risk of future rheumatoid arthritis: a nested case-control study","volume":"15","author":"Arkema","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"10.1016\/j.jaut.2024.103299_bib28","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/art.42248","article-title":"Longitudinal immune cell profiling in patients with early systemic lupus erythematosus","volume":"74","author":"Sasaki","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"20","key":"10.1016\/j.jaut.2024.103299_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130062","article-title":"PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21","volume":"4","author":"Bocharnikov","year":"2019","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.jaut.2024.103299_bib30","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.40180","article-title":"Peripheral immunophenotyping identifies three subgroups based on T cell heterogeneity in lupus patients","volume":"69","author":"Kubo","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"10.1016\/j.jaut.2024.103299_bib31","first-page":"1861","article-title":"Expanded circulating peripheral helper T cells in systemic lupus erythematosus: association with disease activity and B cell differentiation","volume":"58","author":"Makiyama","year":"2019","journal-title":"Rheumatology"},{"issue":"18","key":"10.1016\/j.jaut.2024.103299_bib32","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1182\/blood.2020008248","article-title":"Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition","volume":"136","author":"Yu","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jaut.2024.103299_bib33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41577-021-00665-1","article-title":"The state of complement in COVID-19","volume":"22","author":"Afzali","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2024.103299_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663187","article-title":"Complement overactivation and consumption predicts in-hospital mortality in SARS-CoV-2 infection","volume":"12","author":"Sinkovits","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2024.103299_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000236","article-title":"Cell-bound complement activation products in SLE","volume":"4","author":"Ramsey-Goldman","year":"2017","journal-title":"Lupus Sci Med"},{"issue":"1","key":"10.1016\/j.jaut.2024.103299_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/art.41093","article-title":"Complement activation in patients with probable systemic lupus erythematosus and ability to predict progression to American College of rheumatology-classified systemic lupus erythematosus","volume":"72","author":"Ramsey-Goldman","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.jaut.2024.103299_bib37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/1047-2797(94)00096-C","article-title":"A connective tissue disease screening questionnaire for population studies","volume":"5","author":"Karlson","year":"1995","journal-title":"Ann. Epidemiol."},{"issue":"1","key":"10.1016\/j.jaut.2024.103299_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/0961203320966378","article-title":"Improving sensitivity of the connective tissue disease screening questionnaire: a comparative study of various scoring methods","volume":"30","author":"Xiang","year":"2021","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.jaut.2024.103299_bib39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chron. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2024.103299_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13317-016-0075-0","article-title":"International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results","volume":"7","author":"Damoiseaux","year":"2016","journal-title":"Auto Immun Highlights"},{"issue":"4","key":"10.1016\/j.jaut.2024.103299_bib41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5114\/reum.2018.77976","article-title":"Antinuclear antibodies in healthy people and non-rheumatic diseases - diagnostic and clinical implications","volume":"56","author":"Grygiel-G\u00f3rniak","year":"2018","journal-title":"Reumatologia"},{"issue":"3","key":"10.1016\/j.jaut.2024.103299_bib42","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/s10165-009-0155-3","article-title":"Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases","volume":"19","author":"Satoh","year":"2009","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jaut.2024.103299_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1746-1596-4-1","article-title":"Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited","volume":"4","author":"Kumar","year":"2009","journal-title":"Diagn. Pathol."},{"issue":"6","key":"10.1016\/j.jaut.2024.103299_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12809","article-title":"Lupus anticoagulant associates with thrombosis in patients with COVID-19 admitted to intensive care units: a retrospective cohort study","volume":"6","author":"Noordermeer","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"10.1016\/j.jaut.2024.103299_bib45","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc2013656","article-title":"Lupus anticoagulant and abnormal coagulation tests in patients with covid-19","volume":"383","author":"Bowles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2024.103299_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.890522","article-title":"Understanding the concept of pre-clinical autoimmunity: prediction and prevention of systemic lupus erythematosus: identifying risk factors and developing strategies against disease development","volume":"13","author":"Choi","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.jaut.2024.103299_bib47","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1136\/annrheumdis-2015-208140","article-title":"Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification","volume":"75","author":"Munroe","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103299_bib48","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.3389\/fimmu.2018.02771","article-title":"Prevalence and incidence of upper respiratory tract infection events are elevated prior to the development of rheumatoid arthritis in first-degree relatives","volume":"9","author":"Arleevskaya","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2024.103299_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002587","article-title":"Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey","volume":"8","author":"DiIorio","year":"2022","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.jaut.2024.103299_bib50","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1136\/ard-2022-222954","article-title":"Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave","volume":"81","author":"Kawano","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.jaut.2024.103299_bib51","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jiac.2022.06.013","article-title":"Temporal trends in clinical characteristics and in-hospital mortality among patients with COVID-19 in Japan for waves 1, 2, and 3: a retrospective cohort study","volume":"28","author":"Endo","year":"2022","journal-title":"J. Infect. Chemother."},{"issue":"4","key":"10.1016\/j.jaut.2024.103299_bib52","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/ard-2022-223439","article-title":"Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases","volume":"82","author":"Patel","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.jaut.2024.103299_bib53","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/S2665-9913(23)00006-1","article-title":"Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study","volume":"5","author":"Qian","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"20","key":"10.1016\/j.jaut.2024.103299_bib54","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1016\/j.vaccine.2022.03.069","article-title":"Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: implications for vaccine strategies","volume":"40","author":"Sughayer","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jaut.2024.103299_bib55","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.2147\/IJGM.S370080","article-title":"Prognostic value of SARS-CoV-2 anti-RBD IgG antibody quantitation on clinical outcomes in hospitalized COVID-19 patients","volume":"15","author":"Madanat","year":"2022","journal-title":"Int. J. Gen. Med."},{"issue":"59","key":"10.1016\/j.jaut.2024.103299_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abh2259","article-title":"Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection","volume":"6","author":"Ma","year":"2021","journal-title":"Sci Immunol"},{"issue":"7836","key":"10.1016\/j.jaut.2024.103299_bib57","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41586-020-2600-6","article-title":"Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis","volume":"588","author":"Carvelli","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jaut.2024.103299_bib58","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jaci.2020.05.006","article-title":"Complement activation in patients with COVID-19: a novel therapeutic target","volume":"146","author":"Cugno","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"11","key":"10.1016\/j.jaut.2024.103299_bib59","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1172\/JCI141374","article-title":"Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis","volume":"130","author":"Skendros","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103299_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103378","article-title":"Clinical features and prognostic factors in Covid-19: a prospective cohort study","volume":"67","author":"de Bruin","year":"2021","journal-title":"EBioMedicine"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124001331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124001331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T13:46:43Z","timestamp":1725803203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841124001331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":60,"alternative-id":["S0896841124001331"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103299","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Earlier vs. later time period of COVID-19 infection and emergent autoimmune signs, symptoms, and serologies","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103299"}}